A Study of Etentamig and Daratumumab in People With Multiple Myeloma

Full Title

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Malin Hultcrantz’s office at 646-608-3714.

Protocol

26-051

Phase

Phase II/III (phases 2 and 3 combined)

Disease Status

Relapsed or Refractory

Investigator

Malin Hultcrantz

Co-Investigators

Neha S. Korde

Diseases

Hematology › Multiple Myeloma

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07095452

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description